Skip to Contents

Hanmi R&D creates a better future for humanity.

Overview

We focus on research areas with high unmet medical needs such as obesity/metabolism, oncology, and rare diseases.

Hanmi Pharmaceutical is a R&D-centric pharmaceutical company that focuses on developing new drugs for a better life for humanity. Hanmi Pharmaceutical is establishing and executing R&D strategies to create powerful, sustainable, and unprecedented innovations focusing on obesity/metabolism, oncology, and rare diseases with high unmet medical needs. Our current main pipeline includes long-acting new bio drugs and dual antibodies based on 'targeted protein control' and Hanmi's unique platform technology, 'LAPSCOVERY.' We also focus on developing FDCs and INDs to improve patient's quality of life. Hanmi Pharmaceutical is discovering new modalities such as 'ADC(antibody-drug conjugate), ' 'Cell/Gene Therapy,' 'mRNA-based Therapy,' and 'TPD(targeted protein degrader)' as next-generation technologies.
  • Primary Focus
  • Exploratory Research
Protein/Peptide
Expansion of long-acting platform technologies
TPM
Development of various targeted therapies
Antibody & Fc
Bispecific antibody-based new drugs
IMD-New Formulation
Fixed-dose combination / Incrementally modified drugs
Antibody-drug conjugate ADC
Discovery of next-generation antibody-drug conjugates
mRNA
mRNA-based anti-cancer vaccines
Cell & Gene
Commercialization of cell & gene therapies
TPD
Targeted protein degradation technologies

R&D Network

We provide an optimal research environment through an organic R&D network with each center so that research-stage candidates can rapidly develop and reach the commercialization stage.

  • Hanmi R&D Center
    • Dongtan, Gyeonggi-do, South Korea
    • New drugs based on our technology and new modalities / New drugs in obesity/metabolism, oncology and rare diseases
    • 150+
  • Global Business Division and New Product Development Division (Headquarters)
    • Songpa-gu, Seoul, South Korea
    • Clinical research, Regulatory affairs, In/out-licensing
    • 120+
  • Pharmaceutical Research Center
    • Paltan, Gyeonggi-do, South Korea
      Gwanggyo, Gyeonggi-do, South Korea
    • Developing combination drugs and new drugs formulation based on drug delivery system
    • 60+
  • Bioprocess Development Team (Pyeongtaek Site)
    • Pyeongtaek, Gyeonggi-do, South Korea
    • Manufacturing and development of recombinant protein products based on microbial fermentation and biochemical conjugation reaction processes
    • 50+
  • Hanmi Fine Chemical R&D Center
    • Sihwa, Gyeonggi-do, South Korea
    • Process development of APIs such as small molecules, peptides, PEGs, and mRNA raw materials
    • 50+
  • Beijing Hanmi R&D Center
    • Beijing, China
    • New bispecific antibodies based on our proprietary PENTAMBODY platform technology
    • 150+